Novavax, Inc. (NVAX): Price and Financial Metrics
NVAX Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.38 for Novavax Inc; that's greater than it is for only 4.8% of US stocks.
- Revenue growth over the past 12 months for Novavax Inc comes in at -45.9%, a number that bests only 3.85% of the US stocks we're tracking.
- In terms of volatility of its share price, NVAX is more volatile than 96.22% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Novavax Inc, a group of peers worth examining would be UMRX, INO, BCRX, MGNX, and PTI.
- Visit NVAX's SEC page to see the company's official filings. To visit the company's web site, go to www.novavax.com.
NVAX Stock Price Chart More Charts
NVAX Price/Volume Stats
Novavax, Inc. (NVAX) Company Bio
Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.